OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer
Launched by BEIHUA KONG ·
Trial Information
Current as of October 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to monitor ovarian cancer in women whose usual blood test (called CA125) doesn’t show signs of the cancer coming back after their first treatment. The study uses a technology called exosome detection, which examines tiny particles released by cells, to see if it can better detect when the cancer might be returning. This could help doctors find a return of the cancer earlier and improve follow-up care.
Women between the ages of 65 and 74 who have ovarian cancer and whose CA125 test was negative at the start of their treatment may be eligible to join. Participants would be monitored using this new exosome-based test to see how well it works in spotting cancer recurrence. Since the trial hasn’t started recruiting yet, interested patients can talk with their doctor to learn more about whether this study might be right for them and what taking part would involve.
Gender
FEMALE
Eligibility criteria
About Beihua Kong
Beihua Kong is a dedicated clinical trial sponsor focused on advancing medical research and innovation through rigorous study design and implementation. With a commitment to enhancing patient outcomes, Beihua Kong collaborates with leading healthcare professionals and institutions to conduct high-quality clinical trials across various therapeutic areas. The organization emphasizes ethical practices, regulatory compliance, and patient safety, ensuring that all trials are conducted with the highest standards of integrity. Through its efforts, Beihua Kong aims to contribute significantly to the development of novel therapies and improve healthcare solutions worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported